Parathyroid hormone (1-34) (human): Mechanistic Benchmarks for Calcium Homeostasis and Bone Metabolism Research

Executive Summary: Parathyroid hormone (1-34) (human) is a synthetic peptide fragment that recapitulates the bioactivity of native parathyroid hormone, acting as a specific agonist at PTH1R and PTH2R to regulate serum calcium levels via cAMP and inositol phosphate pathways [APExBIO]. The peptide has a defined sequence (H2N-SVSEIQLMHNLGKHLNSMERVEWLRKKLQDVHNF-OH), MW 4117.72 Da, and demonstrates an IC50 of 0.22 nM for cAMP stimulation in human kidney 293 cells. It has been benchmarked in vivo for dose-dependent augmentation of trabecular and cortical bone mass in rat models, supporting osteoporosis and kidney disease modeling (Huang et al., 2025). The product, supplied by APExBIO, is provided at >97.8% purity and is soluble at ≥399.3 mg/mL in DMSO and ≥19.88 mg/mL in water, but insoluble in ethanol, with storage stability at -20°C. This reference article systematizes its validated use cases, mechanistic pathways, and integration into advanced kidney assembloid workflows.

Biological Rationale

Parathyroid hormone (1-34) (human), also known as PTH (1-34), is a truncated yet fully active form of human parathyroid hormone, encompassing the N-terminal 34 amino acids. These residues are essential for high-affinity receptor binding and signal transduction [APExBIO]. The endogenous full-length hormone is secreted by the chief cells of the parathyroid glands and is the primary physiological regulator of serum calcium concentration in humans and mammals. The biological rationale for using the (1-34) fragment is its preservation of the full hormonal spectrum of activity—bone resorption, renal calcium reabsorption, and stimulation of vitamin D activation—while offering greater stability and synthetic accessibility compared to the full-length (1-84) peptide (Huang et al., 2025).

Recent advances in kidney assembloid and organoid models, such as spatially patterned human kidney progenitor assembloids, highlight the need for precise regulators of mineral metabolism for disease modeling and regenerative medicine (Huang et al., 2025). Parathyroid hormone (1-34) (human) enables researchers to dissect calcium signaling, bone-kidney axis crosstalk, and the downstream effects of PTH/PTHrP receptor agonism under controlled conditions. Compared to earlier reviews, this article systematically analyzes the peptide’s atomic mechanisms and in vitro/in vivo benchmarks, extending insights from previous mechanistic explorations by providing explicit evidence links and workflow guidance.

Mechanism of Action of Parathyroid hormone (1-34) (human)

PTH (1-34) functions as a high-affinity agonist at the parathyroid hormone 1 receptor (PTH1R) and parathyroid hormone 2 receptor (PTH2R), both members of the class B G protein-coupled receptor (GPCR) superfamily. Upon ligand binding, PTH1R undergoes a conformational change to activate the Gs protein, leading to increased intracellular cyclic AMP (cAMP) production. This is quantitatively supported by its IC50 of 0.22 nM for cAMP stimulation in HEK293 cells expressing PTH1R [APExBIO]. The peptide also activates the Gq pathway, resulting in inositol phosphate synthesis and subsequent mobilization of intracellular calcium stores. These signaling pathways orchestrate the following physiological effects:

• Bones: Enhanced osteoclastic bone resorption, releasing calcium and phosphate into circulation.
• Kidneys: Increased reabsorption of calcium and magnesium in the distal tubules and thick ascending limb, with decreased phosphate reabsorption.
• Intestine: Upregulation of 1,25-dihydroxyvitamin D (calcitriol) synthesis, increasing intestinal absorption of dietary calcium.

These effects are reproduced by the synthetic fragment, making it a robust tool for dissecting PTH/PTHrP receptor signaling in experimental models (see also: a translational perspective). This article clarifies receptor subtype specificity, downstream effector pathways, and the quantitative benchmarks for cAMP/intracellular Ca²⁺ dynamics.

Evidence & Benchmarks

• PTH (1-34) (human) stimulates cAMP with an IC50 of 0.22 nM in HEK293 cells transfected with human PTH1R, confirming high receptor affinity and potency (APExBIO).
• In vivo, subcutaneous administration of 10 or 40 μg/kg/day in male Fisher 344 rats results in dose- and time-dependent increases in both trabecular and cortical bone mass (APExBIO).
• The peptide fragment is stable as a solid at -20°C and maintains >97.8% purity under desiccated conditions (APExBIO).
• Solubility is ≥399.3 mg/mL in DMSO and ≥19.88 mg/mL in water, but the peptide is insoluble in ethanol (APExBIO).
• Advanced kidney assembloid models require physiologically relevant PTH signaling for accurate modeling of calcium handling and mineral metabolism (Huang et al., 2025).
• Current organoid models often lack mature, spatially organized nephron-collecting duct architectures, limiting their ability to recapitulate late-onset kidney disease (Huang et al., 2025).
• PTH (1-34) is not intended for clinical or diagnostic use, but is validated for experimental and preclinical applications only (APExBIO).

Applications, Limits & Misconceptions

Applications:

• Bone metabolism research: Establishes dose-dependent anabolic and catabolic effects on bone, supporting osteoporosis model development.
• Kidney disease modeling: Facilitates studies on renal calcium reabsorption and PTH/PTHrP receptor signaling in kidney assembloid and organoid systems (Huang et al., 2025).
• Workflow integration: Used as a reference agonist for PTH1R, enabling quantitative assays of cAMP, inositol phosphate, and Ca²⁺ flux.

Compared to recent discussions on experimental reliability, this article extends guidance by summarizing precise solubility, storage, and purity parameters for cross-laboratory reproducibility.

Common Pitfalls or Misconceptions

• PTH (1-34) (human) is not suitable for diagnostic or therapeutic use in humans; it is strictly for research applications [APExBIO].
• The fragment does not recapitulate the C-terminal signaling or clearance properties of full-length (1-84) PTH.
• Peptide is insoluble in ethanol; improper solvent use can lead to aggregation or loss of activity.
• Long-term storage of diluted solutions is discouraged due to loss of potency; always use freshly prepared aliquots.
• Kidney organoids lacking proper spatial nephron/collecting duct patterning may not accurately model PTH-regulated physiology (Huang et al., 2025).

Workflow Integration & Parameters

For optimal results, dissolve Parathyroid hormone (1-34) (human) in DMSO at concentrations up to 399.3 mg/mL or in water at up to 19.88 mg/mL. Avoid ethanol. Store solid peptide desiccated at -20°C. Prepare aliquots for single-use to prevent freeze-thaw cycles that degrade peptide integrity. When integrating into cellular models, titrate concentrations to match physiological ranges (typically in the low nanomolar range for PTH1R activation). For in vivo rodent studies, validated dosing is 10–40 μg/kg/day subcutaneously. For kidney assembloid experiments, reference recent protocols that match spatially patterned nephron and collecting duct architectures (Huang et al., 2025).

This article clarifies peptide characteristics and handling, updating and extending the workflow guidance from earlier mechanistic best-practices reviews by providing explicit solubility, storage, and dosing parameters.

Conclusion & Outlook

Parathyroid hormone (1-34) (human) (SKU A1129) from APExBIO is a validated, high-purity research reagent enabling high-fidelity studies of calcium homeostasis, bone metabolism, and kidney disease modeling. Its atomic characterization, receptor specificity, and quantitative benchmarks support reproducible results across multi-system experimental platforms. As kidney assembloid and organoid models advance toward higher physiological fidelity, the precise use and understanding of PTH (1-34) will be essential for dissecting mineral metabolism and translational pathophysiology. For further details, visit the product page.